Following Pfizer / biontech and Modena's two mRNA vaccines, the United States has announced the results of phase 3 of the new coronal vaccine developed by Johnson & Johnson, with a protection rate of 72% for Americans and 57% for South Africa.
Different from the mRNA technology route, the new coronal vaccine ad26. Cov2. S developed by Johnson & Johnson company adopts ad26 adenovirus vector technology, which is one of the five mainstream routes of new coronal vaccine at present. At present, three inactivated vaccines are mainly developed in China.
According to the results of phase 3 test, the results of protection rate are different due to the tests conducted in 8 countries around the world,In the United States, the protection rate was 72%, in Latin America it was 66%, in South Africa it was 57%, and the overall protection rate was 66%.
However, the novel coronavirus pneumonia rate is higher than that of adults. The effective rate of prevention of severe new crown pneumonia is 85% in adults within 4 weeks after inoculation.
Although the protection rate is much lower than that of the mRNA vaccine, Johnson's vaccine is highly expected because it has two obvious advantages,One is that it only needs one injection, but it doesn't need ultra-low temperature storage. It can be stored in a standard refrigerator.
These two advantages are very suitable for large-scale vaccination, which not only reduces the cost, but also simplifies the procedure.
Johnson & Johnson is expected to provide 100 million doses of vaccine to the U.S. market in the first half of this year, 200 million doses to the European Union by the end of April, and 200 million doses to developing countries in the second half of this year.
- THE END -
Reprint please indicate the source: fast technology